Table of Contents
PPT Slide
Major points considered
EWG Charge
Biomarker Definition
Characteristics of an ‘ideal’ biomarker
Key Questions
List of Current Cardiotoxicity Biomarkers
Cardiotoxicity Biomarkers on the [Near] Horizon
Identification & Validation of New Biomarkers - Interagency Coordinating Committee on Validation of Alternative Methods (ICCVAM)
Identification & Validation of New Biomarkers - Toxicologist Consensus
How can the FDA enable this process? - Confidentiality
How can the FDA enable this process? - Financial support
Next Steps in Fulfilling EWG’s Charge
Possible outcomes?
|
Author: Kendall B. Wallace, Ph.D.
|